Literature DB >> 7194946

Acute and chronic cisplatin nephropathy in rats.

D D Choie, D S Longnecker, A A del Campo.   

Abstract

Cisplatin (cis-dichlorodiammineplatinum-II) is a new class of platinum coordination compounds showing a potent antitumor activity, but it also produces adverse effects on renal function. In this study, cisplatin nephropathy and renal accumulation of platinum were analyzed in rats after acute chronic treatment. A single intraperitoneal dose of cisplatin (6 mg. per kg.) induced marked focal necrosis in the proximal and distal tubules with a maximal lesion on day 7. The tubular damage was localized mainly in the corticomedullary region, where the concentration of platinum was the highest within the kidney. Repeated treatment with cisplatin (1 mg. per kg., intraperitoneally, twice weekly) for 11 weeks resulted in massive tubular basement membranes. Some glomeruli appeared fibrotic, indicating that chronic treatment with cisplatin could cause irreversible renal damage. The results indicated that the toxicity of platinum was probably a major factor for cisplatin nephropathy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7194946

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  20 in total

1.  Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews.

Authors:  Julie L Eiseman; Jan H Beumer; Lora H Rigatti; Sandra Strychor; Kelly Meyers; Samuel Dienel; Charles C Horn
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-15       Impact factor: 3.333

2.  Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment.

Authors:  G Los; P H Mutsaers; W J Lenglet; G S Baldew; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Carcinogenic effect of cisplatin (cis-diammine-dichloroplatinum (II), CDDP) in BD IX rats.

Authors:  S R Kempf; S Ivankovic
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

4.  Cyst formation in metanephric organ culture induced by cis-dichlorodiammineplatinum (II).

Authors:  E D Avner; W E Sweeney; D Ellis
Journal:  Experientia       Date:  1983-01-15

5.  Potentiated nephrotoxicity of cisplatin when combined with amikacin comparing young and adult rats.

Authors:  H T Jongejan; A P Provoost; J C Molenaar
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

6.  Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.

Authors:  D J Stewart; C Dulberg; J M Molepo; N Z Mikhael; V A Montpetit; M D Redmond; R Goel
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 7.  Cisplatin: a review of clinical applications and renal toxicity.

Authors:  D T Sleijfer; S Meijer; N H Mulder
Journal:  Pharm Weekbl Sci       Date:  1985-12-13

8.  Follow-up study of enzymuria and beta 2 microglobulinuria during cis-platinum treatment.

Authors:  A S Tirelli; N Colombo; G Cavanna; C Mangioni; B M Assael
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Long-term studies of cisplatin-induced reductions in porcine renal functional reserve.

Authors:  M E Robbins; T B Bywaters; R S Jaenke; J W Hopewell; L M Matheson; P Tothill; E Whitehouse
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Renal immunolocalization of kallikrein in cisplatin nephrotoxicity in rats.

Authors:  C Orfila; G Bompart; J C Lepert; J M Suc; J P Girolami
Journal:  Histochem J       Date:  1993-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.